AbioCor implantable replacement heart procedure performed by University of Louisville surgeons
Additional information will be available at a news briefing to be held on Wednesday, July 4th at 10:00 a.m. atop the Rudd Heart and Lung Center on the Jewish Hospital campus, 201 Abraham Flexner Way. Additional information will not be released prior to the news briefing. This is consistent with the Company's previously announced "quiet period" policy intended to protect patient confidentiality and allow for the best possible medical care.
Based in Danvers, Massachusetts, Abiomed, Inc. is a leading developer, manufacturer and marketer of medical products designed to assist or replace the pumping function of the failing heart. The Company's first generation AbioCor Implantable Replacement Heart is being implanted in selected patients as part of an initial clinical trial conducted under an Investigational Device Exemption (IDE) from the United States Food and Drug Administration (FDA). The AbioCor has not been approved for commercial distribution, and is not available for use or sale outside of the initial clinical trial. Abiomed currently manufactures and sells the BVS, a heart assist advice for the temporary support of all patients with failing but potentially recoverable hearts.
Jewish Hospital is among the top ten cardiac centers in the United States and, along with the University of Louisville, is dedicated to excellence, research and education. University of Louisville surgeons at Jewish Hospital have performed many heart care "firsts," including Kentucky's first heart transplant, the world's first endoscopic saphenous vein harvest and the first ventricular remodeling in the region.
Source: Abiomed, Inc.
Subscribe to our free e-mail newsletter.
Click for a free Buyer's Guide listing.